Metsera, Inc. Common Stock (MTSR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Metsera, Inc. Common Stock (MTSR) has a cash flow conversion efficiency ratio of -0.131x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.96 Million) by net assets ($449.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MTSR net asset value for net asset value and shareholders' equity analysis.
Metsera, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Metsera, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Metsera, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Metsera, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nordstrom Inc
NYSE:JWN
|
0.786x |
|
MiniMed Group, Inc. Common Stock
NASDAQ:MMED
|
0.019x |
|
AGL Energy Ltd
AU:AGL
|
0.115x |
|
EO Technics Co. Ltd
KQ:039030
|
0.038x |
|
Brinks Company
NYSE:BCO
|
0.073x |
|
Liaoning Port Co Ltd
SHG:601880
|
0.032x |
|
Changsha Jingjia Microelectronics Co Ltd
SHE:300474
|
-0.013x |
|
Shenzhen FRD Science & Technology Co Ltd
SHE:300602
|
0.042x |
Annual Cash Flow Conversion Efficiency for Metsera, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Metsera, Inc. Common Stock from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see Metsera, Inc. Common Stock (MTSR) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $287.35 Million | $-100.04 Million | -0.348x | +3.11% |
| 2023-12-31 | $98.50 Million | $-35.39 Million | -0.359x | -154.40% |
| 2022-12-31 | $-813.00K | $-537.00K | 0.661x | -- |
About Metsera, Inc. Common Stock
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to re… Read more